Canada markets open in 22 minutes

Protagenic Therapeutics, Inc. (PTIX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.7200-0.0100 (-0.58%)
At close: 04:00PM EST
1.6800 -0.04 (-2.33%)
Pre-Market: 08:35AM EST

Protagenic Therapeutics, Inc.

149 Fifth Avenue
Suite 500
New York, NY 10010
United States
212 994 8200

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Garo H. Armen Ph.D.Co-Founder & Exec. ChairmanN/AN/A1953
Dr. Alexander Kenneth Arrow C.F.A., M.D.CFO & Sec.38.46kN/A1971
Dr. Andrew SleeChief Operating OfficerN/AN/A1950
Dr. Robert Benjamin Stein M.D., Ph.D.Chief Medical Officer & DirectorN/AN/A1951
Dr. David A. LovejoyChief Scientific Officer, Scientific Founder & Scientific AdvisorN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.

Corporate Governance

Protagenic Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.